Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD
Abstract Background The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length N...
Saved in:
| Published in | The international journal of neuropsychopharmacology Vol. 27; no. 12; p. 1 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
US
Oxford University Press
01.12.2024
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1461-1457 1469-5111 1469-5111 |
| DOI | 10.1093/ijnp/pyae062 |
Cover
Loading…
| Abstract | Abstract
Background
The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD.
Methods
Rats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA).
Results
Sitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels.
Conclusions
The findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. |
|---|---|
| AbstractList | The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD.
Rats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA).
Sitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels.
The findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. Abstract Background The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD. Methods Rats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA). Results Sitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels. Conclusions The findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. Background The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD. Methods Rats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA). Results Sitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels. Conclusions The findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. Background: The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length [NPY.sub.1-36] induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD. Methods: Rats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA). Results: Sitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels. Conclusions: The findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. Keywords: animal model, post-traumatic stress disorder (PTSD), neuropeptide Y, neuropeptide Y-Y1 receptor, resilience, vulnerability, dipeptidyl peptidase-IV The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD.BACKGROUNDThe regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD.Rats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA).METHODSRats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA).Sitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels.RESULTSSitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels.The findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses.CONCLUSIONSThe findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. |
| Audience | Academic |
| Author | Cohen, Hagit Todder, Doron Dahan, Matan Zohar, Joseph Mathé, Aleksander A |
| Author_xml | – sequence: 1 givenname: Matan surname: Dahan fullname: Dahan, Matan – sequence: 2 givenname: Joseph surname: Zohar fullname: Zohar, Joseph – sequence: 3 givenname: Doron surname: Todder fullname: Todder, Doron – sequence: 4 givenname: Aleksander A orcidid: 0000-0002-6946-532X surname: Mathé fullname: Mathé, Aleksander A – sequence: 5 givenname: Hagit orcidid: 0000-0002-4762-1969 surname: Cohen fullname: Cohen, Hagit email: hagitc@bgu.ac.il |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39626016$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:160467232$$DView record from Swedish Publication Index |
| BookMark | eNp9ks1vFCEYxompse3qzbMh8aAHp4WZhYGT2bRVN6m6idXEE2GYl122szDOR9v572U_qm6jhgNv4Pc88MJzjA588IDQc0pOKJHZqVv6-rQeNBCePkJHdMxlwiilB5uaJnTM8kN03LZLQtIxy_gTdJhJnnJC-RG6vrirq9A4P8fdAvDE37lQDZ0zeBY68J3TFQ4Wf5p9x8WANT53NdSdK4cKzzaFbiGZfsNTv3CF60KDncfaRyO3itKPoYSNwezqy_lT9NjqqoVnu3mEvr67uDr7kFx-fj89m1wmhjHSJUZK4FKkVtpM6IKLDEpGDWTMCgtWaMKkzUuthc2lNJoXshAyA2lZrjWj2QglW9_2Fuq-UHUT79IMKmindkvXsQIlZE74OPJvt3zcWUFpYtuNrvZk-zveLdQ83ChKOctI_IQRer1zaMKPHtpOrVxroKq0h9C3KqNjIlNG8zyiLx-gy9A3Pr5HpLjgIieC_abmugLlvA3xYLM2VRORilTSePNInfyFiqOElTMxJtbF9T3Biz87_dXifR4ikG4B04S2bcAq4zrdubBu3FWKErUOnVqHTu1CF0VvHojuff-Bv9rioa__T_4EXZDoBA |
| CitedBy_id | crossref_primary_10_1016_j_ejphar_2025_177556 |
| Cites_doi | 10.1038/s41598-018-27395-0 10.1021/bi9714767 10.1007/s11064-023-03924-w 10.1016/S0006-8993(99)02119-8 10.1073/pnas.220232997 10.1146/annurev.neuro.27.070203.144206 10.1016/0166-4328(93)90103-W 10.1016/0306-4522(86)90057-6 10.1523/JNEUROSCI.0659-07.2008 10.1073/pnas.94.21.11686 10.1016/S0899-9007(00)00410-X 10.1088/2050-6120/3/2/025004 10.1016/S0031-9384(03)00229-4 10.1016/j.phrs.2020.104769 10.1210/en.2014-1192 10.1016/j.neuroscience.2013.01.040 10.1016/S0091-3057(03)00154-0 10.1016/j.neuropharm.2014.10.007 10.1016/0167-0115(93)90431-7 10.1016/j.euroneuro.2009.08.004 10.1196/annals.1314.014 10.1385/JMN:18:1-2:07 10.1016/j.ejphar.2016.02.003 10.1016/j.pharmthera.2020.107503 10.1016/j.peptides.2006.07.020 10.1515/revneuro-2022-0026 10.3389/fnbeh.2021.705579 10.1016/j.euroneuro.2017.11.006 10.1523/JNEUROSCI.5361-07.2008 10.1016/0278-5846(89)90003-1 10.1007/s10787-017-0331-6 10.1016/S0166-2236(98)01284-3 10.1210/en.2011-0286 10.1210/endo-117-6-2435 10.1016/j.npep.2019.101979 10.1016/j.regpep.2014.05.001 10.1517/14728222.2011.628314 10.1177/153537020322800301 10.1016/j.psyneuen.2015.01.007 10.1007/s12035-016-0125-7 10.1016/j.npep.2016.02.007 10.1016/j.euroneuro.2013.11.007 10.1016/j.npep.2015.11.004 10.1016/j.peptides.2006.09.027 10.3389/fnbeh.2019.00017 10.1017/S1461145707007912 10.1038/npp.2011.230 10.4103/1673-5374.249217 10.1016/S0149-7634(01)00066-5 10.1016/j.npep.2015.09.010 10.1530/eje.0.1400130 10.4103/1673-5374.177724 10.1016/j.physbeh.2007.05.016 10.1007/s11011-014-9603-7 10.1016/0166-2236(94)90046-9 10.2337/db12-0988 10.1038/306584a0 10.1016/j.npep.2004.05.002 10.1016/j.biopsych.2005.04.002 10.1016/S0014-2999(00)00230-2 10.1016/S0006-3223(02)01909-1 10.1111/cns.12475 10.1073/pnas.87.1.182 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024. Published by Oxford University Press on behalf of CINP. 2024 The Author(s) 2024. Published by Oxford University Press on behalf of CINP. COPYRIGHT 2024 Oxford University Press The Author(s) 2024. Published by Oxford University Press on behalf of CINP. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024. Published by Oxford University Press on behalf of CINP. 2024 – notice: The Author(s) 2024. Published by Oxford University Press on behalf of CINP. – notice: COPYRIGHT 2024 Oxford University Press – notice: The Author(s) 2024. Published by Oxford University Press on behalf of CINP. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | TOX AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1093/ijnp/pyae062 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1469-5111 |
| ExternalDocumentID | oai_swepub_ki_se_897064 PMC11653009 A828291706 39626016 10_1093_ijnp_pyae062 10.1093/ijnp/pyae062 |
| Genre | Journal Article |
| GeographicLocations | Israel |
| GeographicLocations_xml | – name: Israel |
| GroupedDBID | --- -E. .FH 0E1 0R~ 0VX 123 29J 3V. 4.4 53G 5VS 74X 74Y 7X7 7~V 88E 8AO 8FI 8FJ 8R4 8R5 AAFWJ AAMVS AAOGV AAPPN AAPXW AAVAP ABEJV ABGNP ABITZ ABIVO ABKKG ABPTD ABQLI ABUWG ABVKB ABXVV ACGFS ACIMK ADBBV ADHZD ADRAZ AEMTW AENEX AENZO AFFVI AFKRA AFULF AFUTZ AHMBA AJ7 ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQC AMNDL AOIJS ARABE AVWKF AZQEC BAWUL BAYMD BCNDV BENPR BPHCQ BTTYL BVXVI C0O CAG CCPQU CIDKT COF CS3 DC4 DIK DU5 DWQXO EBS EJD EMOBN FYUFA GNUQQ GROUPED_DOAJ H13 HG- HMCUK HST HYE HZ~ I.6 IAO IHR ITC I~P J36 J38 J3A KQ8 KSI L98 M-V M1P M2M M48 ML0 M~E O9- OAWHX OJQWA OK1 P2P PEELM PIMPY PQQKQ PROAC PSQYO PSYQQ Q2X RHF RIG ROL ROX RPM RR0 S6- S70 TJX TOX TUQ UKHRP UU6 WQ3 WXU WYP AAYXX AFPKN CITATION CGR CUY CVF ECM EIF NPM K9. 7X8 5PM ADTPV AOWAS D8T PHGZM PHGZT PJZUB PPXIY PUEGO ZZAVC |
| ID | FETCH-LOGICAL-c550t-c99e6982f9f38ab683ed51ce35f8fef8a059f7daa8f799ca6b9b893e9f57aa513 |
| IEDL.DBID | M48 |
| ISSN | 1461-1457 1469-5111 |
| IngestDate | Mon Sep 01 03:35:22 EDT 2025 Thu Aug 21 18:29:54 EDT 2025 Fri Jul 11 03:23:31 EDT 2025 Mon Jun 30 12:34:02 EDT 2025 Tue Jun 17 21:59:22 EDT 2025 Tue Jun 10 21:00:27 EDT 2025 Sat Aug 16 01:30:49 EDT 2025 Tue Jul 01 03:53:31 EDT 2025 Thu Apr 24 23:11:31 EDT 2025 Tue Feb 04 08:58:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | dipeptidyl peptidase-IV neuropeptide Y post-traumatic stress disorder (PTSD) vulnerability animal model resilience neuropeptide Y-Y1 receptor |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. https://creativecommons.org/licenses/by-nc/4.0 The Author(s) 2024. Published by Oxford University Press on behalf of CINP. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c550t-c99e6982f9f38ab683ed51ce35f8fef8a059f7daa8f799ca6b9b893e9f57aa513 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-6946-532X 0000-0002-4762-1969 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1093/ijnp/pyae062 |
| PMID | 39626016 |
| PQID | 3168687085 |
| PQPubID | 43629 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_897064 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11653009 proquest_miscellaneous_3140925177 proquest_journals_3168687085 gale_infotracmisc_A828291706 gale_infotracacademiconefile_A828291706 pubmed_primary_39626016 crossref_citationtrail_10_1093_ijnp_pyae062 crossref_primary_10_1093_ijnp_pyae062 oup_primary_10_1093_ijnp_pyae062 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-01 |
| PublicationDateYYYYMMDD | 2024-12-01 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: England – name: Oxford |
| PublicationTitle | The international journal of neuropsychopharmacology |
| PublicationTitleAlternate | Int J Neuropsychopharmacol |
| PublicationYear | 2024 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Clark (2024121808561072800_CIT0011) 1985; 117 Canneva (2024121808561072800_CIT0010) 2015; 53 Sántha (2024121808561072800_CIT0053) 2015; 8 Vezzani (2024121808561072800_CIT0062) 1999; 22 Böhm (2024121808561072800_CIT0008) 1997; 322 (Pt 1) Welcome (2024121808561072800_CIT0066) 2020; 157 Krysiak (2024121808561072800_CIT0040) 1999; 140 White (2024121808561072800_CIT0067) 1993; 49 Ramamoorthy (2024121808561072800_CIT0069) 2008; 28 Cohen (2024121808561072800_CIT0012) 2004; 1032 Adrian (2024121808561072800_CIT0001) 1983; 306 Sajdyk (2024121808561072800_CIT0052) 2008; 28 Nahvi (2024121808561072800_CIT0047) 2019; 13 Cohen (2024121808561072800_CIT0017) 2013; Chapter 9 Waget (2024121808561072800_CIT0063) 2011; 152 Small (2024121808561072800_CIT0059) 1997; 94 Cohen (2024121808561072800_CIT0016) 2012; 37 Serova (2024121808561072800_CIT0055) 2014; 24 Fuhlendorff (2024121808561072800_CIT0026) 1990; 87 Bacchi (2024121808561072800_CIT0003) 2006; 27 Heilig (2024121808561072800_CIT0030) 1995; 9 Kastin (2024121808561072800_CIT0036) 2002; 18 Gøtzsche (2024121808561072800_CIT0028) 2016; 55 Berglund (2024121808561072800_CIT0006) 2003; 228 Sabban (2024121808561072800_CIT0051) 2016; 56 Heilig (2024121808561072800_CIT0029) 2004; 38 Kalra (2024121808561072800_CIT0031) 1999; 20 Badawi (2024121808561072800_CIT0004) 2017; 25 Cohen (2024121808561072800_CIT0013) 2003; 53 Cohen (2024121808561072800_CIT0018) 2018; 28 Mathé (2024121808561072800_CIT0044) 2007; 92 Frerker (2024121808561072800_CIT0025) 2007; 28 Mousa (2024121808561072800_CIT0046) 2019; 14 Srinivas (2024121808561072800_CIT0060) 2015; 21 Gainetdinov (2024121808561072800_CIT0027) 2004; 27 Kempf (2024121808561072800_CIT0037) 2015; 3 Karl (2024121808561072800_CIT0034) 2003; 80 Paxinos (2024121808561072800_CIT0070) 2013 Wahlestedt (2024121808561072800_CIT0065) 1989; 13 Wu (2024121808561072800_CIT0068) 2011; 15 Karl (2024121808561072800_CIT0033) 2003; 75 Michel (2024121808561072800_CIT0045) 1998; 50 Ayoub (2024121808561072800_CIT0002) 2018; 8 Nahvi (2024121808561072800_CIT0048) 2021; 15 Cohen (2024121808561072800_CIT0015) 2008; 11 Sharma (2024121808561072800_CIT0057) 2015; 30 Laukova (2024121808561072800_CIT0041) 2014; 155 Lin (2024121808561072800_CIT0042) 2016; 11 Corder (2024121808561072800_CIT0020) 2020; 79 Thorsell (2024121808561072800_CIT0061) 2000; 97 Redrobe (2024121808561072800_CIT0050) 1999; 848 Kask (2024121808561072800_CIT0035) 2002; 26 Siddiqui (2024121808561072800_CIT0058) 2023; 48 Cohen (2024121808561072800_CIT0014) 2005; 58 Kosaraju (2024121808561072800_CIT0039) 2017; 54 Serova (2024121808561072800_CIT0054) 2013; 236 Beck (2024121808561072800_CIT0005) 2000; 16 Wagner (2024121808561072800_CIT0064) 2016; 57 Brakch (2024121808561072800_CIT0009) 1997; 36 Nassar (2024121808561072800_CIT0049) 2015; 89 Colmers (2024121808561072800_CIT0019) 1994; 17 Darsalia (2024121808561072800_CIT0021) 2013; 62 King (2024121808561072800_CIT0038) 2000; 396 Lin (2024121808561072800_CIT0043) 2010; 20 Darsalia (2024121808561072800_CIT0022) 2014; 190-191 de Quidt (2024121808561072800_CIT0023) 1986; 18 Kamble (2024121808561072800_CIT0032) 2016; 774 Bernstein (2024121808561072800_CIT0007) 2023; 34 Shao (2024121808561072800_CIT0056) 2020; 209 File (2024121808561072800_CIT0024) 1993; 58 |
| References_xml | – volume: 8 start-page: 8959 year: 2018 ident: 2024121808561072800_CIT0002 article-title: Repositioning of omarigliptin as a once-weekly intranasal anti-parkinsonian agent publication-title: Sci Rep doi: 10.1038/s41598-018-27395-0 – volume: 36 start-page: 16309 year: 1997 ident: 2024121808561072800_CIT0009 article-title: Role of prohormone convertases in pro-neuropeptide Y processing: coexpression and in vitro kinetic investigations publication-title: Biochemistry doi: 10.1021/bi9714767 – volume: 48 start-page: 2714 year: 2023 ident: 2024121808561072800_CIT0058 article-title: Neuroprotective role of DPP-4 inhibitor linagliptin against neurodegeneration, neuronal insulin resistance and neuroinflammation induced by intracerebroventricular streptozotocin in rat model of Alzheimer’s disease publication-title: Neurochem Res doi: 10.1007/s11064-023-03924-w – volume: 848 start-page: 153 year: 1999 ident: 2024121808561072800_CIT0050 article-title: Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition publication-title: Brain Res doi: 10.1016/S0006-8993(99)02119-8 – volume: 97 start-page: 12852 year: 2000 ident: 2024121808561072800_CIT0061 article-title: Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.220232997 – volume: 27 start-page: 107 year: 2004 ident: 2024121808561072800_CIT0027 article-title: Desensitization of G protein-coupled receptors and neuronal functions publication-title: Annu Rev Neurosci doi: 10.1146/annurev.neuro.27.070203.144206 – volume: 58 start-page: 199 year: 1993 ident: 2024121808561072800_CIT0024 article-title: The interplay of learning and anxiety in the elevated plus-maze publication-title: Behav Brain Res doi: 10.1016/0166-4328(93)90103-W – volume: 18 start-page: 545 year: 1986 ident: 2024121808561072800_CIT0023 article-title: Distribution of neuropeptide Y-like immunoreactivity in the rat central nervous system--II. Immunohistochemical analysis publication-title: Neuroscience doi: 10.1016/0306-4522(86)90057-6 – volume: 28 start-page: 893 year: 2008 ident: 2024121808561072800_CIT0052 article-title: Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0659-07.2008 – volume: 8 start-page: 88 year: 2015 ident: 2024121808561072800_CIT0053 article-title: Restraint stress-induced morphological changes at the blood-brain barrier in adult rats publication-title: Front Mol Neurosci – volume: 94 start-page: 11686 year: 1997 ident: 2024121808561072800_CIT0059 article-title: Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.94.21.11686 – volume: 50 start-page: 143 year: 1998 ident: 2024121808561072800_CIT0045 article-title: XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors publication-title: Pharmacol Rev – volume: 16 start-page: 916 year: 2000 ident: 2024121808561072800_CIT0005 article-title: Neuropeptides and obesity publication-title: Nutrition doi: 10.1016/S0899-9007(00)00410-X – volume: 3 start-page: 025004 year: 2015 ident: 2024121808561072800_CIT0037 article-title: Internalization mechanism of neuropeptide Y bound to its Y(1) receptor investigated by high resolution microscopy publication-title: Methods Appl Fluoresc doi: 10.1088/2050-6120/3/2/025004 – volume: 80 start-page: 123 year: 2003 ident: 2024121808561072800_CIT0034 article-title: Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences publication-title: Physiol Behav doi: 10.1016/S0031-9384(03)00229-4 – volume: 157 start-page: 104769 year: 2020 ident: 2024121808561072800_CIT0066 article-title: Stress-induced blood brain barrier disruption: Molecular mechanisms and signaling pathways publication-title: Pharmacol Res doi: 10.1016/j.phrs.2020.104769 – volume: 155 start-page: 3920 year: 2014 ident: 2024121808561072800_CIT0041 article-title: Early intervention with intranasal NPY prevents single prolonged stress-triggered impairments in hypothalamus and ventral hippocampus in male rats publication-title: Endocrinology doi: 10.1210/en.2014-1192 – volume: 20 start-page: 68 year: 1999 ident: 2024121808561072800_CIT0031 article-title: Interacting appetite-regulating pathways in the hypothalamic regulation of body weight publication-title: Endocr Rev – volume: 236 start-page: 298 year: 2013 ident: 2024121808561072800_CIT0054 article-title: Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats publication-title: Neuroscience doi: 10.1016/j.neuroscience.2013.01.040 – volume: Chapter 9 start-page: Unit 9.45 year: 2013 ident: 2024121808561072800_CIT0017 article-title: Animal models of post-traumatic stress disorder publication-title: Curr Protoc Neurosci – volume: 75 start-page: 869 year: 2003 ident: 2024121808561072800_CIT0033 article-title: Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity publication-title: Pharmacol Biochem Behav doi: 10.1016/S0091-3057(03)00154-0 – volume: 89 start-page: 308 year: 2015 ident: 2024121808561072800_CIT0049 article-title: Saxagliptin: a novel antiparkinsonian approach publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.10.007 – volume: 49 start-page: 93 year: 1993 ident: 2024121808561072800_CIT0067 article-title: Neuropeptide Y: a central regulator of energy homeostasis publication-title: Regul Pept doi: 10.1016/0167-0115(93)90431-7 – volume: 20 start-page: 164 year: 2010 ident: 2024121808561072800_CIT0043 article-title: Adult-onset hippocampal-specific neuropeptide Y overexpression confers mild anxiolytic effect in mice publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2009.08.004 – volume: 1032 start-page: 167 year: 2004 ident: 2024121808561072800_CIT0012 article-title: An animal model of posttraumatic stress disorder: the use of cut-off behavioral criteria publication-title: Ann N Y Acad Sci doi: 10.1196/annals.1314.014 – volume: 18 start-page: 7 year: 2002 ident: 2024121808561072800_CIT0036 article-title: Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier publication-title: J Mol Neurosci doi: 10.1385/JMN:18:1-2:07 – volume: 774 start-page: 64 year: 2016 ident: 2024121808561072800_CIT0032 article-title: Neurobehavioral effects of liraglutide and sitagliptin in experimental models publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2016.02.003 – volume: 209 start-page: 107503 year: 2020 ident: 2024121808561072800_CIT0056 article-title: Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2020.107503 – volume: 27 start-page: 3202 year: 2006 ident: 2024121808561072800_CIT0003 article-title: Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze publication-title: Peptides doi: 10.1016/j.peptides.2006.07.020 – volume: 34 start-page: 1 year: 2023 ident: 2024121808561072800_CIT0007 article-title: The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview publication-title: Rev Neurosci doi: 10.1515/revneuro-2022-0026 – volume: 15 start-page: 705579 year: 2021 ident: 2024121808561072800_CIT0048 article-title: Intranasal neuropeptide Y as a potential therapeutic for depressive behavior in the rodent single prolonged stress model in females publication-title: Front Behav Neurosci doi: 10.3389/fnbeh.2021.705579 – volume: 28 start-page: 159 year: 2018 ident: 2024121808561072800_CIT0018 article-title: Neuropeptide S in the basolateral amygdala mediates an adaptive behavioral stress response in a rat model of posttraumatic stress disorder by increasing the expression of BDNF and the neuropeptide YY1 receptor publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2017.11.006 – volume: 28 start-page: 13815 issue: : year: 2008 ident: 2024121808561072800_CIT0069 article-title: Trafficking and fusion of neuropeptide Y-containing dense-core granules in astrocytes publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5361-07.2008 – volume: 13 start-page: 31 year: 1989 ident: 2024121808561072800_CIT0065 article-title: Neuropeptide Y (NPY) and the central nervous system: distribution effects and possible relationship to neurological and psychiatric disorders publication-title: Prog Neuropsychopharmacol Biol Psychiatry doi: 10.1016/0278-5846(89)90003-1 – volume: 25 start-page: 369 year: 2017 ident: 2024121808561072800_CIT0004 article-title: Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease publication-title: Inflammopharmacology doi: 10.1007/s10787-017-0331-6 – volume: 22 start-page: 25 year: 1999 ident: 2024121808561072800_CIT0062 article-title: Neuropeptide Y: emerging evidence for a functional role in seizure modulation publication-title: Trends Neurosci doi: 10.1016/S0166-2236(98)01284-3 – volume: 152 start-page: 3018 year: 2011 ident: 2024121808561072800_CIT0063 article-title: Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice publication-title: Endocrinology doi: 10.1210/en.2011-0286 – volume: 117 start-page: 2435 year: 1985 ident: 2024121808561072800_CIT0011 article-title: Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats publication-title: Endocrinology doi: 10.1210/endo-117-6-2435 – volume: 79 start-page: 101979 year: 2020 ident: 2024121808561072800_CIT0020 article-title: Overexpression of neuropeptide Y decreases responsiveness to neuropeptide Y publication-title: Neuropeptides doi: 10.1016/j.npep.2019.101979 – volume: 190-191 start-page: 25 year: 2014 ident: 2024121808561072800_CIT0022 article-title: Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice publication-title: Regul Pept doi: 10.1016/j.regpep.2014.05.001 – volume: 15 start-page: 1317 year: 2011 ident: 2024121808561072800_CIT0068 article-title: Central functions of neuropeptide Y in mood and anxiety disorders publication-title: Expert Opin Ther Targets doi: 10.1517/14728222.2011.628314 – volume: 228 start-page: 217 year: 2003 ident: 2024121808561072800_CIT0006 article-title: Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes publication-title: Exp Biol Med (Maywood) doi: 10.1177/153537020322800301 – volume: 53 start-page: 195 year: 2015 ident: 2024121808561072800_CIT0010 article-title: DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2015.01.007 – volume: 54 start-page: 6074 year: 2017 ident: 2024121808561072800_CIT0039 article-title: Linagliptin, a dipeptidyl peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer’s disease publication-title: Mol Neurobiol doi: 10.1007/s12035-016-0125-7 – volume: 57 start-page: 21 year: 2016 ident: 2024121808561072800_CIT0064 article-title: Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation publication-title: Neuropeptides doi: 10.1016/j.npep.2016.02.007 – volume: 24 start-page: 142 year: 2014 ident: 2024121808561072800_CIT0055 article-title: Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model publication-title: Eur Neuropsychopharmacol doi: 10.1016/j.euroneuro.2013.11.007 – volume: 56 start-page: 19 year: 2016 ident: 2024121808561072800_CIT0051 article-title: Potential of neuropeptide Y for preventing or treating post-traumatic stress disorder publication-title: Neuropeptides doi: 10.1016/j.npep.2015.11.004 – volume: 28 start-page: 257 year: 2007 ident: 2024121808561072800_CIT0025 article-title: Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4 publication-title: Peptides doi: 10.1016/j.peptides.2006.09.027 – year: 2013 ident: 2024121808561072800_CIT0070 publication-title: The rat brain in stereotaxic coordinates – volume: 13 start-page: 17 year: 2019 ident: 2024121808561072800_CIT0047 article-title: Single prolonged stress as a prospective model for posttraumatic stress disorder in females publication-title: Front Behav Neurosci doi: 10.3389/fnbeh.2019.00017 – volume: 11 start-page: 331 year: 2008 ident: 2024121808561072800_CIT0015 article-title: Post-traumatic stress behavioural responses in inbred mouse strains: can genetic predisposition explain phenotypic vulnerability publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145707007912 – volume: 37 start-page: 350 year: 2012 ident: 2024121808561072800_CIT0016 article-title: The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder publication-title: Neuropsychopharmacology doi: 10.1038/npp.2011.230 – volume: 14 start-page: 745 year: 2019 ident: 2024121808561072800_CIT0046 article-title: Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents publication-title: Neural Regen Res doi: 10.4103/1673-5374.249217 – volume: 26 start-page: 259 year: 2002 ident: 2024121808561072800_CIT0035 article-title: The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y publication-title: Neurosci Biobehav Rev doi: 10.1016/S0149-7634(01)00066-5 – volume: 322 (Pt 1) start-page: 1 year: 1997 ident: 2024121808561072800_CIT0008 article-title: Regulatory mechanisms that modulate signalling by G-protein-coupled receptors publication-title: Biochem J – volume: 55 start-page: 79 year: 2016 ident: 2024121808561072800_CIT0028 article-title: The role of NPY in learning and memory publication-title: Neuropeptides doi: 10.1016/j.npep.2015.09.010 – volume: 9 start-page: 115 year: 1995 ident: 2024121808561072800_CIT0030 article-title: Neurobiology and clinical aspects of neuropeptide Y publication-title: Crit Rev Neurobiol – volume: 140 start-page: 130 year: 1999 ident: 2024121808561072800_CIT0040 article-title: Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis publication-title: Eur J Endocrinol doi: 10.1530/eje.0.1400130 – volume: 11 start-page: 236 year: 2016 ident: 2024121808561072800_CIT0042 article-title: The neuroprotective effects of the anti-diabetic drug linagliptin against Aβ-induced neurotoxicity publication-title: Neural Regen Res doi: 10.4103/1673-5374.177724 – volume: 92 start-page: 226 year: 2007 ident: 2024121808561072800_CIT0044 article-title: Search for biological correlates of depression and mechanisms of action of antidepressant treatment modalities. Do neuropeptides play a role publication-title: Physiol Behav doi: 10.1016/j.physbeh.2007.05.016 – volume: 30 start-page: 659 year: 2015 ident: 2024121808561072800_CIT0057 article-title: Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats publication-title: Metab Brain Dis doi: 10.1007/s11011-014-9603-7 – volume: 17 start-page: 373 year: 1994 ident: 2024121808561072800_CIT0019 article-title: Effects of neuropeptide Y on the electrical properties of neurons publication-title: Trends Neurosci doi: 10.1016/0166-2236(94)90046-9 – volume: 62 start-page: 1289 year: 2013 ident: 2024121808561072800_CIT0021 article-title: The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride publication-title: Diabetes doi: 10.2337/db12-0988 – volume: 306 start-page: 584 year: 1983 ident: 2024121808561072800_CIT0001 article-title: Neuropeptide Y distribution in human brain publication-title: Nature doi: 10.1038/306584a0 – volume: 38 start-page: 213 year: 2004 ident: 2024121808561072800_CIT0029 article-title: The NPY system in stress, anxiety and depression publication-title: Neuropeptides doi: 10.1016/j.npep.2004.05.002 – volume: 58 start-page: 640 year: 2005 ident: 2024121808561072800_CIT0014 article-title: Unsupervised fuzzy clustering analysis supports behavioral cutoff criteria in an animal model of posttraumatic stress disorder publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2005.04.002 – volume: 396 start-page: R1 year: 2000 ident: 2024121808561072800_CIT0038 article-title: Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release publication-title: Eur J Pharmacol doi: 10.1016/S0014-2999(00)00230-2 – volume: 53 start-page: 463 year: 2003 ident: 2024121808561072800_CIT0013 article-title: The relevance of differential response to trauma in an animal model of posttraumatic stress disorder publication-title: Biol Psychiatry doi: 10.1016/S0006-3223(02)01909-1 – volume: 21 start-page: 962 year: 2015 ident: 2024121808561072800_CIT0060 article-title: Linagliptin-role in the reversal of Aβ-mediated impairment of insulin signaling and reduced neurotoxicity in AD pathogenesis: some considerations publication-title: CNS Neurosci Ther doi: 10.1111/cns.12475 – volume: 87 start-page: 182 year: 1990 ident: 2024121808561072800_CIT0026 article-title: [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.87.1.182 |
| SSID | ssj0024536 |
| Score | 2.442951 |
| Snippet | Abstract
Background
The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its... The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5... Background: The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects... Background The regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects... |
| SourceID | swepub pubmedcentral proquest gale pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | Animals Anti-Anxiety Agents - administration & dosage Anti-Anxiety Agents - pharmacology Anxiety Anxiety - drug therapy Behavior Behavior, Animal - drug effects Dipeptidyl-Peptidase IV Inhibitors - pharmacology Disease Models, Animal Drug therapy Enzyme-linked immunosorbent assay Health aspects Male Methods Neuropeptide Y Neuropeptide Y - metabolism Neuropeptide Y - pharmacology Peptides Post traumatic stress disorder Rats Rats, Sprague-Dawley Regular Sitagliptin Sitagliptin Phosphate - pharmacology Stress Disorders, Post-Traumatic - drug therapy Stress Disorders, Post-Traumatic - metabolism Testing |
| Title | Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39626016 https://www.proquest.com/docview/3168687085 https://www.proquest.com/docview/3140925177 https://pubmed.ncbi.nlm.nih.gov/PMC11653009 http://kipublications.ki.se/Default.aspx?queryparsed=id:160467232 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELem8cIL4puMMhkJygMLa5rYsR8QqhjThsSIRIvKU-QkthZWnNJ10vLfc5e4KeFD8BJF8fmc2Hf2Ob77HSHPdMBUoDX3x1IbPyo0nu-q0FdFXoyDLMfYAfS2OOMns-j9nM13yCbbqOvAyz9u7TCf1Gy1eHX9vX4DCv_agSEdll_t8nBZKz3CyfgGrEkxquiHSGxR91jo4owCP4hY7Fzgf63dW5zcFN2Le_vJ_Pzdi7KHNdqsT8e3yS1nWNJJKwl3yI62d8kwaZGp6wM63QZaXR7QIU22mNX1PXLR-eJRsAjpxF6X1aIGWppUa3QoAtaVoWfJF5rVVNGjconuMEW9oElzA4uhf_qZntrzMoNJYkVLS5UFRuU3qIoZ1xoGyfTT0X0yO343fXviuzwMfg77l7WfS6m5FGMjTShUxkWoCxbkOmRGGG2EAhPNxIVSwsRS5opnMgMzSEvDYqVYED4gu7ay-hGhbKRZg0bKRRTFYJrxEcLfBHxUxCrLY4-83AxAmjuQcsyVsUjbw_IwxeFK3XB55HlHvWzBOf5C9wLHMkUpAm65cqEH8E6IfpVOBJ4nI5CQRwY9StC1vFdMQRr-0dZgIyrpRppTzA7GYWYUzCNPu2Jkji5uVldXSANbbQSQg0542EpW11AoeQP95hHRk7mOAEHC-yW2PG_AwhFeKQSN88iwFc9eHffoAu50KiR8YrT3n536mNwcg2K1rj0DsrteXeknYKCts_3mx8Z-o4FwnX6c_wCRlz_Z |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exploring+the+Anxiolytic+Potential+of+NPY+by+a+Dipeptidyl+Peptidase-IV+Inhibitor+in+an+Animal+Model+of+PTSD&rft.jtitle=The+international+journal+of+neuropsychopharmacology&rft.au=Dahan%2C+Matan&rft.au=Zohar%2C+Joseph&rft.au=Todder%2C+Doron&rft.au=Math%C3%A9%2C+Aleksander+A&rft.date=2024-12-01&rft.issn=1461-1457&rft.eissn=1469-5111&rft.volume=27&rft.issue=12&rft_id=info:doi/10.1093%2Fijnp%2Fpyae062&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ijnp_pyae062 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1461-1457&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1461-1457&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1461-1457&client=summon |